Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCFinancial_Report.xls
10-Q - FORM 10-Q - PHARMACEUTICAL PRODUCT DEVELOPMENT INCd10q.htm
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 1350 - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex321.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex312.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex311.htm
EX-10.279 - TWELFTH AMENDMENT TO LEASE AGREEMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10279.htm
EX-10.278 - CONFIRMATION WITH BARCLAYS BANK PLC - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10278.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Pharmaceutical Product Development, Inc. (“PPD”) on Form 10-Q for the period ended March 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel G. Darazsdi, Chief Financial Officer of PPD, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of PPD as of, and for, the periods presented in the Report.

Date: May 3, 2011

 

/s/ Daniel G. Darazsdi
Daniel G. Darazsdi
Chief Financial Officer